Analyst picks & changes

Analyst picks & changes

Analyst picks & changes
CompanyBankAnalystCoverageOpinionWk chg12/19 cls
BioDelivery Sciences International Inc. (NASDAQ:BDSI)Roth Capital PartnersScott HenryUpgradeBuy (from neutral)0%$13.82
Henry upgraded after a recent decline in BioDelivery's share price of about 25% since the November launch of Bunavail buprenorphine/naloxone as a maintenance treatment for opioid dependence. Henry said the decline suggests that investors are unimpressed by early prescription data. However, he remains bullish on BEMA Buprenorphine (EN3409), "the main driver to the valuation," with a filing expected in early 2015. The transmucosal

Read the full 812 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE